Veronica DiCamillo is an adept transactional lawyer who has handled a wide range of both US and international mergers and acquisitions and other corporate transactions. She represents public and private companies, private equity funds, and investment banks in a diverse array of business transactions, including US and cross-border mergers, acquisitions, divestitures, investments, carve-outs, joint ventures, strategic alliances, tender offers, spinoffs, venture capital financings, and corporate reorganizations.
Veronica’s broad client base spans a variety of industries, including pharmaceuticals and healthcare, manufacturing, consumer goods and retail, food and beverage, technology services including fintech, media and entertainment, and shipping. Veronica has acquired experience in the life sciences industry through her frequent representations of both public and private pharmaceutical, specialty pharmaceutical, biotech, and medical device companies in connection with structuring and executing developed and early-stage product acquisitions and divestitures, company sales and acquisitions, business unit spinoffs, and postacquisition integration on a national and global scale.
In addition to her significant transactional background, she frequently counsels clients on securities law compliance, corporate governance, and other general corporate matters. Additionally, Veronica is actively engaged in pro bono work with a focus on counseling nonprofits on various legal issues and representing individual clients in asylum cases.
Before joining Morgan Lewis, Veronica was senior counsel in the corporate department of another global law firm, resident in New York. As a junior associate, she completed a secondment at UBS Investment Bank. Prior to graduating law school, Veronica served as a member of the Fordham Law Review and interned with Judge Shira Sheindlin in the US District Court for the Southern District of New York.
Life Sciences Transactions
Represented Cosette Pharmaceuticals, Inc., a specialty pharmaceutical company, in its acquisition of the US sales and distribution rights to eight branded commercial products from Daiichi Sankyo Company, Ltd.
Represented Amneal Pharmaceuticals, Inc. in its acquisition of Saol Therapeutic’s baclofen franchise as well as a pipeline product under development
Represented Cell IDx, Inc. in its sale to Leica Biosystems through a reverse merger
Represented Edenbridge Pharmaceuticals, LLC in its sale to Dexcel Pharma
Represented Amneal Pharmaceuticals, Inc. in its acquisition of a majority interest in AvKARE and its related affiliate doing business as R&S Northeast, a large private label provider of generic pharmaceuticals in the US federal agency sector
Represented Advanz Pharma Corp. in connection with its acquisition of the international rights to Salagen® and Panretin® from Eisai Inc.
Represented Merck in connection with the spinoff of Organon & Co. to create a new global healthcare company focusing on women’s health
Represented PTC Therapeutics in its acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company, for cash and stock
Represented Perrigo Company in the divestiture of its animal health business to PetIQ
Represented Pfizer, Inc. in connection with the global restructuring and spinoff of its Animal Health business, which is now Zoetis, Inc., and the global restructuring and $11.8 billion sale of its Nutrition business to Nestlé S.A.
Represented Valeant Pharmaceuticals International, Inc. in connection with its acquisition through a tender offer of Obagi Medical Products, Inc.; transaction was valued at $440 million
Represented a large pharmaceutical company in connection with purchasing an option to acquire a company upon the US Food and Drug Administration’s approval of its drug
Represented a large pharmaceutical company in connection with its minority investment in a startup maker of personalized medicine suites
Strategic Mergers & Acquisitions
Represented HBR Holdings in its divestiture of its advisory business to private equity firm Renovus Capital; as part of the transaction, HBR’s advisory business was carved out as a standalone business from its information technology and managed services businesses
Represented TrueSight Solutions LLC, a provider of third-party vendor risk assessments, in its acquisition by S&P Global
Represented MAI Capital Management, a registered investment adviser, in its acquisition of Intersect Capital, a wealth management firm
Represented Virtu Financial, Inc. in its formation of, and sale of assets to, RFQ-hub Holdings LLC, a consortium among Virtu; the leading electronic trading platform MarketAxess; liquidity providers Citadel Securities, Flow Traders, and Jane Street Capital; and asset manager BlackRock
Represented iTi Tropicals, Inc., a producer of plant-based products and fruit juice purees and concentrates, in its acquisition by Shore Capital Partners
Represented Liberty Property Trust in its all-stock acquisition by Prologis, Inc. for $13 billion
Represented Utilant LLC, a US-based insurtech company, in its sale to Majesco, a global provider of cloud insurance platform software
Represented PotashCorp in connection with its $38 billion all-stock merger of equals with Agrium
Represented Chindex International, Inc. in connection with its going-private transaction
Represented a division of CVS Pharmacy in its acquisition of two home healthcare businesses
Represented a US financial institution in connection with the sale of its railcar leasing portfolio
Represented an investment firm in its $100 million acquisition of a Swiss private bank
Represented a privately held financial services firm in connection with its $535 million acquisition of a commercial financing and leasing company
Represented a US-based cable television provider/multiple system operator in an auction involving the sale of certain of its cable assets and entities to a US private equity firm; transaction was valued at $500 million
Represented Ares Private Equity Group in connection with its sale of its controlling stake in SVP Worldwide, a consumer sewing machine company, to Platinum Equity
Represented LLR Partners in its investment in True Search, a global executive talent management platform
Represented a US private equity investment firm in connection with the divestiture of its minority interest in four entertainment companies
Represented a US private equity investor in its acquisition of a leading global experiential marketing solutions company
Represented Wasserstein & Co., LP in connection with the purchase of Recorded Books, a supplier of audiobooks, ebooks, and other electronic content to libraries
Represented a US private equity investor in connection with its minority investment in a mobile technology accessory manufacturer
Represented a US private equity investor in connection with the sale of its truck dealership group to a US private equity firm
Fordham University School of Law, 2007, J.D.
New York University, 2004, B.A., Economics and Fine Arts, cum laude